CMPI - CMPI STOCK NEWS

Checkmate Pharmaceuticals (CMPI) reported its Q2 2021 financial results, highlighting ongoing clinical trials for vidutolimod aimed at treating melanoma and head and neck cancer. Notable collaborations with Bristol Myers Squibb support various trials, with initial data readouts expected in 2022. R&D expenses rose to $14.9 million, largely due to a $4.0 million milestone payment. General and administrative expenses also increased to $4.1 million. The company maintains a strong cash position of $95.6 million as of June 30, 2021, bolstering its ability to execute clinical programs.

Checkmate Pharmaceuticals (NASDAQ: CMPI) announced that CEO Barry Labinger will present at the BTIG Virtual Biotechnology Conference on August 9, 2021, from 3:30-3:55 PM ET. The clinical-stage biopharmaceutical company is focused on developing its proprietary technology to utilize the immune system against cancer, particularly through its product candidate, vidutolimod (CMP-001), a TLR9 agonist.

Additionally, Checkmate will host 1x1 investor meetings during the conference. More information can be found at www.checkmatepharma.com.

Checkmate Pharmaceuticals (NASDAQ: CMPI) announced that CEO Barry Labinger will present at the Jefferies Virtual Healthcare Conference on June 1, 2021, from 2:00-2:25pm ET. The event will include 1x1 investor meetings. A live webcast is available on the company's website under 'Events & Presentations' and will be archived for 30 days. Checkmate is focused on leveraging the immune system to fight cancer, with its lead product candidate, vidutolimod (CMP-001), being a TLR9 agonist designed to enhance tumor attacks.

Checkmate Pharmaceuticals (CMPI) reported its Q1 2021 financial results, highlighting significant progress in its clinical trials for vidutolimod, an immune-based cancer treatment. The company initiated patient dosing in three key trials for melanoma and head and neck cancer, with plans to expand into non-melanoma skin cancers in collaboration with Regeneron. R&D expenses rose to $10.4 million, partly due to a $2 million milestone payment. G&A expenses increased to $3.8 million. As of March 31, 2021, Checkmate held $111.5 million in cash and investments.

Checkmate Pharmaceuticals (NASDAQ: CMPI) announced the expansion of its clinical development program for vidutolimod (CMP-001) into non-melanoma skin cancers in collaboration with Regeneron Pharmaceuticals. The multi-indication, Phase 2 trial will assess vidutolimod’s efficacy combined with Libtayo (cemiplimab) in patients with cutaneous squamous cell carcinoma and Merkel cell carcinoma. As the trial’s sponsor, Checkmate aims to enhance the potential of immuno-oncology therapeutics targeting life-threatening skin cancers.

Checkmate Pharmaceuticals (NASDAQ: CMPI) announced the initiation of patient dosing in a Phase 2 trial for vidutolimod (CMP-001) combined with nivolumab, targeting anti-PD-1 refractory advanced melanoma. This trial aims to evaluate the safety and efficacy of this combination therapy. Melanoma is among the most diagnosed cancers in the U.S., with significant unmet needs for patients who have progressed post anti-PD-1 therapy. The trial's data could support a biologics license application for the treatment.

Checkmate Pharmaceuticals, a clinical stage biopharmaceutical company, announced that CEO Barry Labinger will present at the Bank of America Securities 2021 Virtual Healthcare Conference on May 12, 2021, at 1:15 PM ET. Additionally, the company will conduct 1x1 investor meetings during the event. A live webcast of the presentation can be accessed on Checkmate's website, along with an archived version available for 45 days post-event. Checkmate focuses on utilizing immune system technology to treat cancer, with its lead product candidate being vidutolimod (CMP-001).

Checkmate Pharmaceuticals (NASDAQ: CMPI) announced the initiation of dosing in a Phase 2 trial for vidutolimod (CMP-001) in patients with head and neck squamous cell carcinoma (HNSCC). This proof-of-concept trial aims to assess the safety and efficacy of vidutolimod combined with pembrolizumab for first-line relapsed or metastatic HNSCC. Initial data is expected by the end of 2021, while comprehensive results are anticipated in the second half of 2022. The trial's importance lies in addressing the limited response rates of existing treatments.

Checkmate Pharmaceuticals (CMPI) announced promising results from its Phase 1b trial of vidutolimod in combination with pembrolizumab for advanced melanoma patients resistant to anti-PD-1 therapy. At the AACR Virtual Clinical Trials session, new translational data showed that a significant 93% of participants had progressive disease previously. Despite high baseline disease severity, the combination treatment demonstrated consistent response rates across various patient characteristics. Notably, clinical responses were linked to serum CXCL10 induction rather than traditional predictive markers.